Jonathan Ramsey, MD
Ophthalmology · Huntsville, ALNPI 1225456858
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,683 of the $8,164 with a category attached, or 81.9%. 22 manufacturers reported payments, led by Alcon at 46.2% of the total. Among ophthalmology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 209 payments — averaging $39.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- Carl Zeiss Meditec USA, Inc.$1K
- AbbVie$823
- Bausch & Lomb, A Division Of Bausch Health US, LLC$297
- Sight Sciences, Inc.$264
- Johnson & Johnson Surgical Vision, Inc.$227
- plus $1K from 16 others
What the payments were for
- Consulting fees$1502%
- Food & beverage$6,68382%
- Other$1,33116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 110 | $3,774 |
| Carl Zeiss Meditec USA, Inc. | 2 | $1,331 |
| AbbVie(2 entities) | 26 | $823 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $297 |
| Sight Sciences, Inc. | 10 | $264 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $227 |
| AstraZeneca | 3 | $168 |
| Sun Pharmaceutical Industries Inc. | 7 | $157 |
| Ivantis, Inc | 1 | $150 |
| Tarsus Pharmaceuticals, Inc. | 8 | $145 |
| Glaukos Corporation | 4 | $134 |
| Astellas Pharma US Inc | 1 | $134 |
| Oyster Point Pharma, Inc. | 4 | $124 |
| Bausch & Lomb Americas Inc. | 6 | $111 |
| Novartis | 4 | $79 |
| Rxsight Inc | 3 | $69 |
| NEW World Medical,inc. | 4 | $68 |
| Ocular Therapeutix, Inc. | 2 | $33 |
| Thea Pharma Inc. | 1 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Eyepoint US, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARTEVO 800$1,331
- Clareon$713
- LenSx$225
- LOTEMAX SM$164
- Hydrus$150
- XEN$146
- Clareon PanOptix Pro$145
- Tecnis Simplicity$135
- ARGOS$134
- XEN GLAUCOMA TREATMENT SYSTEM$112
- SOLIRIS$110
How this compares
$8,164 in reported general payments places this provider in the 90th percentile of 197 ophthalmology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 16 | $25,298 |
| RestasisCyclosporine | 21 | $18,197 |
| Latanoprost | 342 | $5,803 |
| Prednisolone Acetate | 77 | $4,029 |
| Brimonidine Tartrate | 203 | $3,082 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 85 | $2,558 |
| ValacyclovirValacyclovir Hcl | 26 | $1,805 |
| Timolol Maleate | 68 | $674 |
| Ofloxacin | 39 | $473 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 20 | $263 |
| ErythromycinErythromycin Base | 16 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $111 | $25,29816 claims |
| AbbVieRestasis | $823 | $18,19721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 197 ophthalmology providers in Alabama.
Other ophthalmology in Huntsville
- Caroline WatsonHuntsville$292K
- William MitchellHuntsville$8K
- Paul FrederickHuntsville$6K
- Robert FosterHuntsville$6K
- Patricia McCoyHuntsville$5K
- Robert StevensHuntsville$5K
- Walter HubickeyHuntsville$4K
- Bret FisherHomewood$545K
- Ronald GrossFairhope$143K
- Kristin BainsBirmingham$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.